MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED (MVP)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MVP - MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.84
20 Feb |
OPEN $0.84 |
HIGH $0.85 |
132,330 LOW $0.78 |
0.075| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 05/03 - ex-div 2c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | -46.3 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 33.1 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 51.6 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -10.8 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -123.66 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -64.53 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -62.50 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | -47.32 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | -64.53 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -25.58 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -11.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 9 M |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 10 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.76 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 3.2 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 9.56 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 36 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 14 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | - |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
MVP STOCK CHART
FNArena News on MVP
| 1 |
FNArena Corporate Results Monitor – 01-09-2023Sep 01 2023 - Australia |
| 2 |
Australian Broker Call *Extra* Edition – Mar 08, 2023Mar 08 2023 - Daily Market Reports |
| 3 |
Australian Broker Call *Extra* Edition – Nov 01, 2022Nov 01 2022 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Oct 11, 2022Oct 11 2022 - Daily Market Reports |
| 5 |
Australian Broker Call *Extra* Edition – Sep 06, 2022Sep 06 2022 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
Behring Margin Outlook Still Main Game For CSLFeb 13 2025 - Australia |
| 2 |
Dr Boreham’s Crucible: Arovella TherapeuticsAug 29 2024 - Small Caps |
| 3 |
ResMed’s Margin Upside ExcitesAug 07 2024 - Australia |
| 4 |
Dr Boreham’s Crucible: Aroa BiosurgeryJul 29 2024 - Small Caps |
| 5 |
CSL Shares Breaking FreeJul 23 2024 - Technicals |
| 6 |
Dr Boreham’s Crucible: SDIJul 19 2024 - Small Caps |
| 7 |
‘Defensive’ Pharmaceutical Wholesalers In FocusJul 18 2024 - Australia |
| 8 |
Twists And Turns Of Telix And Australian BiotechJul 10 2024 - Small Caps |
| 9 |
Dr Boreham’s Crucible: Radiopharm TheranosticsJul 03 2024 - Small Caps |
| 10 |
Dr Boreham’s Crucible: Island TherapeuticsJun 17 2024 - Small Caps |